FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549
-------------	------	-------

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

	OMB APPROVAL								
	OMB Number: 3235-028 Estimated average burden								
	hours per response:	0.5							

(Instr. 4)

or Indirect (I) (Instr. 4)

D

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

	uon 1(b).			riieu		ion 30(h) of the							4					
Name and Address of Reporting Person* Treanor Patrick				2. Issuer Name and Ticker or Trading Symbol KalVista Pharmaceuticals, Inc. [KALV]								(Che	Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner					
(Last)	(F	irst)	(Middle)		3. Date of Earliest Transaction (Month/Day/Year) 09/26/2023								•	(give title	Other (speci below)		·	
C/O KALVISTA PHARMACEUTICALS, INC. 55 CAMBRIDGE PARKWAY, SUITE 901E				4. If Amendment, Date of Original Filed (Month/Day/Year)						Line	6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person							
(Street) CAMBRIDGE MA 02142													Form filed by More than One Reporting Person					
(City)	(City) (State) (Zip) Check this box to indicate that a transaction was made pur satisfy the affirmative defense conditions of Rule 10b5-1(c)								pursuant (1(c). See	nstructio	n 10.		plan tha	at is intended	I to			
1. Title of Security (Instr. 3) 2. Trans. Date				2. Transa	Execution Date,		, 3 T C	3. Transaction Code (Instr.		4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 4			(A) or	5. Amou Securitie Beneficia Owned F	5. Amount of Securities Beneficially Owned Following		: Direct Indirect str. 4)	7. Nature of Indirect Beneficial Ownership
					c	Code	v	Amount		(A) or (D)	Price	Transact	Reported Transaction(s) (Instr. 3 and 4)			(Instr. 4)		
		-				urities Acq s, warrants		•					-	Owned				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of	xercise (Month/Day/Year) if any Code (In		ansaction ode (Instr.	5. Number of Derivative Securities	6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and An of Securities Underlying Derivative Sec			•	Derivative derivative Security Securities		:	10. Ownership Form: Direct (D)	11. Nature of Indirect Beneficial Ownership				

buy) **Explanation of Responses:**

\$10.08

Security

1. The option vests over a 12 month period: 1/12th on October 26, 2023, after which 1/12th of the total shares vest monthly, subject to continued service through each vesting date.

(A)

10,000

٧

Α

Acquired (A) or Disposed

of (D) (Instr. 3, 4 and 5)

Date

Exercisable

(1)

(D)

Expiration

09/25/2033

Remarks:

Stock Option

(right to

/s/ Benjamin L. Palleiko,

(Instr. 3 and 4)

Title

Common

Amount or Number

Shares

10,000

\$0.00

09/28/2023

Owned Following

Reported Transaction(s) (Instr. 4)

10,000

Attorney-in-Fact ** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

09/26/2023

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.